2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism

Inclusion criteria

• The subject is male or female ≥ 40 years old;
• The individual has one of these three conditions:
• probable PSP according to criteria of the National Institute of Neurological Disorders and Stroke (NINDS)
• probable MSA according to criteria of the Second consensus statement on the diagnosis of multiple system atrophy
• unclassifiable parkinsonism according to criteria defined by Katzenschlager et al, 2003:
• Patients with atypical parkinsonism without response to treatment with levodopa and does not meet any of the diagnostic criteria for other known atypical parkinsonism
• Patient given written consent

Exclusion criteria

• The subject is diagnosed with Parkinson's Disease and meets the diagnostic criteria United Kingdom Parkinson's Disease Society Brain Bank -The subject is pregnant or breastfeeding;
• The subject has a history of drug abuse or alcohol;
• The subject has a moderate or severe renal function impairment (creatinine serum> 1.5 mg / dL);
• The subject has a moderate or severe hepatic impairment (bilirubin> 2 times the upper limit of normal, transaminases> 3 times the limit top of normal);
• The subject presents structural abnormalities in the basal ganglia or cortical level on MRI or CT;
• The subject has participated in a clinical study with a pharmaceutical product investigation within 30 days prior to screening and / or a radiopharmaceutical minimum period of 5 radioactive half-lives prior to screening;
• Occupational exposure to radiation> 15 milliSievert (mSv) / year
• Use of nonsteroidal antiinflammatory drug (NSAIDs), for some reason, can not be replaced by any other drug 4 weeks before the PET scan;
• The subject has allergy investigational product or any of its components;
• The subject has a clinically severe active disease, with a hope reduced life;
• The subject is claustrophobic / a.